Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 10/20 | 0.50 |
| ▸ | PNMT | P11086 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.41 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13698268 | 0.90 | SIGMAR1 (0.52) | SIGMAR1CYP1A2CYP2D6TMEM97DRD2 | |
| SCHEMBL13698294 | 0.86 | SIGMAR1 (0.45) | SIGMAR1PNMTCYP1A2CYP2D6TMEM97 | |
| SCHEMBL13698270 | 0.80 | CYP2D6 (0.42) | SIGMAR1CYP1A2CYP2D6TMEM97 | |
| SCHEMBL7528803 | 0.67 | SIGMAR1 (1.00) | SIGMAR1CYP1A2CYP2D6TMEM97TP53 | |
| SCHEMBL2922701 | 0.67 | SIGMAR1 (0.62) | SIGMAR1DRD2DRD3 | |
| SCHEMBL11938899 | 0.67 | SIGMAR1 (0.77) | SIGMAR1CYP1A2CYP2D6TMEM97 | |
| SCHEMBL13698300 | 0.66 | RAB9A (0.36) | DRD2DRD3 | |
| SCHEMBL13698247 | 0.64 | DRD2 (0.60) | SIGMAR1KDM2BDRD2DRD3 | |
| SCHEMBL3860327 | 0.63 | DRD2 (0.57) | SIGMAR1DRD2DRD3 | |
| SCHEMBL19261820 | 0.62 | SIGMAR1 (0.48) | SIGMAR1CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8461196-B2 | 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders | DOV PHARMACEUTICAL | 2013-06-11 | — | — | US | disclosed |
| US-20120302619-A1 | Novel 1-aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders | OTSUKA AMERICA PHARMACEUTICAL, INC. | 2012-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120302619-A1 | Novel 1-aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders | HTR3C, HTR1B, HTR2C | SIGMAR1 1402/4885PNMT 57/4885CYP1A2 188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.